ESMO 2023 Update - KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author:…
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung…
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng,…
LIBRETTO-431: Randomized phase III study of selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive advanced NSCLC Author: Dr. Anam Kamal Selpercatinib…
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III…
Presented by: Andrei Iagaru, MD Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center,…
Presented by: Pauline Funchain, M.D, Associate Professor of Medicine Stanford University, Stanford, CA. Covered by: Abdul Moiz Khan, M.D, Chief…
Presented by: Ulka Vaishampayan, M.D., Professor of Medicine/GU Oncology at University of Michigan School of Medicine, Ann Arbor, MI. Covered…
Presented by: Arlene Siefker-Radtke, M.D, Professor of Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer…
Presented by: Russell K Pachynski M.D, Associate Professor and Director of GU Oncology Research at The Division of Oncology, Siteman…